Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Scripps Research Institute Creates New Drug Discovery Initiative

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Scripps Advance is a new drug discovery initiative to translate early-stage biomedical research projects into clinical development candidates.

Scripps Advance’s first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.

"Scripps Advance is a truly novel type of relationship designed to combine the diversity and innovation of academic research enterprises with the expertise, infrastructure and capital of the private sector,” said Scott Forrest, Ph.D., TSRI's vice president of business development. “We believe this collaboration structure will prove uniquely effective. Advance will look both inside and outside of TSRI for projects to take forward and it will work with pharma companies to select and fund those projects. Johnson & Johnson Innovation is committed to innovative science, which only raises our level of excitement about Advance.”

Johnson & Johnson Innovation Center in California will tap into Scripps Advance’s strong ties with academic researchers at TSRI, other academic centers and early stage companies to help identify potential collaborators. As part of the relationship, Advance will facilitate match-making between Johnson & Johnson Innovation and emerging life science companies, companies-in-planning, researchers conducting translational research and entrepreneurs that are part of Scripps Advance’s network.

Scripps Advance has already been active in the biotech space, collaborating with Atlas Venture, an early stage investment firm, to launch a company called Padlock Therapeutics. Padlock discovers novel therapeutics targeting the protein arginine deiminases (PADs), an emerging class of enzymes with roles in autoimmunity and epigenetic control. Padlock’s technology was developed in the laboratories of TSRI investigators Paul Thompson, Ph.D., and Kerri Mowen, Ph.D., in collaboration with the Scripps Florida’s high-throughput screening facility.

Todd Huffman, Ph.D., TSRI’s director of drug discovery partnerships, said, “In building Scripps Advance we recognized the need to focus on therapeutic developments with the potential to lead to game changing ways in which we treat disease. The expertise and technical breadth found at our Florida site has already had a significant impact on putting drug candidates into the clinic. We look forward to broadening our footprint in this area through collaborations with Johnson & Johnson Innovation and other companies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
Monday, March 14, 2016
$6 Million Awarded to Develop Alternative HIV/AIDS Vaccine
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded up to nearly $6 million from the Bill & Melinda Gates Foundation to develop a revolutionary HIV/AIDS alternative vaccine that has demonstrated great potential in animal models.
Thursday, September 24, 2015
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
Thursday, August 06, 2015
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
Thursday, October 30, 2014
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Thursday, October 30, 2014
Chemists Discover Cancer Drug Candidate Structure
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. FDA for clinical trials in cancer patients.
Wednesday, May 21, 2014
New Findings from The Scripps Research Institute Could Help Improve Development of Drugs for Addiction
Scientists have described findings that could enable the development of more effective drugs for addiction with fewer side effects.
Thursday, August 08, 2013
Micah Niphakis Receives ACS Scarborough Award
Niphakis’s research focuses on the development of chemical tools to comprehensively map bioactive molecule-protein interactions in the cell.
Monday, January 21, 2013
Scripps Scientists Reveal How Genetic Mutations May Cause Type 1 Diabetes
The new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.
Monday, May 03, 2010
Team Led by Scripps Research Scientists Develops Technique to Determine Ethnic Origin of Stem Cell Lines
Cells more representative of U.S. and world population could lead to more accurate research and safer, effective therapites.
Monday, January 04, 2010
Scripps Researchers Identify Novel Hepatitis C Inhibitors
New inhibitors have the potential to substantially widen the current options to treat HCV infection.
Thursday, December 24, 2009
Paper Finds Microdroplet PCR Enrichment Ideal Targeted Sequencing Solution for Large-Scale Population Studies
UCSD study evaluated microdroplet PCR’s advantages in performing sequence enrichment for targeted sequencing over traditional PCR approach.
Thursday, November 05, 2009
Team Led by Scripps Research Scientists Finds new Way that Cells Fix Damage to DNA
Proteins responsible for this type of DNA repair may also limit the effectiveness of chemotherapy agents, which aim to injure tumor DNA.
Monday, June 15, 2009
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!